A Review of Planned, Ongoing Clinical Studies and Recent Development of BNCT in Mainland of China

Boron neutron capture therapy (BNCT) is a promising cancer treatment modality that combines targeted boron agents and irradiation to selectively destroy tumor cells. In mainland China, the clinical implementation of BNCT has made certain progress, primarily driven by development compact source devices. The availability, ease operation, cost-effectiveness offered these sources make more accessible centers. Two sources, one being miniature reactor-based (IHNI-1) other accelerator-based (NeuPex), have entered research phase are planned for medical device registration. Moreover, several devices employing different technical routes currently under construction, further expanding options implementation. addition, serves as an experimental platform advancing new agents. Several teams actively involved in Various types third-generation been tested studied vitro vivo. Compared radiotherapy therapies, China still faces specific challenges due its limited trial data support wide range professional fields. To facilitate widespread adoption BNCT, it crucial establish relevant standards devices, agents, protocols.